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ABSTRACT
Objectives: To investigate the extent to which
variation exists in the initiation rate of statin therapy for
the primary prevention of cardiovascular disease
between countries of the UK and between different
regions within England.
Design: Cohort study using data from a large UK
primary care database.
Setting: UK.
Participants: 4 820 885 individuals from 554 general
practices during the period 2004–2012.
Main outcome measures: Rate of statin therapy
initiation per 1000 person-years.
Results: Relative to a fixed English rate of 1 initiation
per 1000 person-years and accounting for gender, age
and social deprivation level, the rate was similar for
Scotland at 0.92 (95% CI 0.84 to 1.00) and rates for
Northern Ireland and Wales were higher at 1.40 (95%
CI 1.20 to 1.62) and 1.18 (95% CI 1.05 to 1.32),
respectively. Within England, the regions could be
classified into three groups with respect to statin
therapy initiation rates (relative to a rate of 1 initiation
per 1000 person-years for London): the South Central
0.73 (95% CI 0.64 to 0.83), South West 0.80 (95% CI
0.71 to 0.91), East of England 0.81 (95% CI 0.71 to
0.94) and South East Coast 0.83 (95% CI 0.73 to
0.95); strategic health authorities had similar low rates
followed by the East Midlands 0.88 (95% CI 0.73 to
1.05), West Midlands 0.96 (95% CI 0.84 to 1.09),
North East 0.96 (95% CI 0.79 to 1.16), Yorkshire and
Humber 0.97 (95% CI 0.81 to 1.17) and London
strategic health authorities. North West England
exhibited the highest rate of statin therapy initiation of
1.16 (95% CI 1.02 to 1.31).
Conclusions: Considerable variation in the rate of
statin therapy initiation was observed between the four
countries of the UK and between different geographical
regions within England.
INTRODUCTION
Statins are a class of lipid-modifying drugs,
commonly prescribed in UK primary care.1
Statins were ﬁrst developed during the
1970s2 3 and the ﬁrst commercially marketed
statin, simvastatin, was introduced in the UK
in the late 1980s.4 Since then, and following
results from several clinical trials,5–8 statins
have become one of the most routinely pre-
scribed class of drugs in the UK.9 The
National Institute for Health and Care
Excellence (NICE) issues guidelines on the
prescription of statins for UK general practi-
tioners (GP). In January 2006, NICE recom-
mended that statin therapy should be
initiated for the primary prevention of car-
diovascular disease (CVD) in adults aged
under 75 years whose 10-year risk of develop-
ing CVD, as calculated using an appropriate
risk score (eg, the Framingham risk score or
QRISK score), exceeds 20%.10 In addition,
NICE recommended that individuals aged
over 75 years could be considered at risk of
CVD regardless of their 10-year CVD risk
Strengths and limitations of this study
▪ We conducted a large-scale analysis of statin
therapy initiation rates within the UK using
recent data from electronic health records. The
large sample size reflects the UK general
population.
▪ We estimated initiation rates between the differ-
ent countries of the UK and between regions
within England, adjusting for patient demo-
graphic variables.
▪ Results showed a wide variation in statin therapy
initiation rates between different general practi-
tioner (GP) practices and some differences
between initiation rates in different geographical
areas/countries.
▪ We only used data from those who are registered
with a GP. However, in the UK, the vast majority
of the population is registered with a GP.
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score and that statin therapy should be considered for
this age group, particularly for individuals at risk such as
smokers or hypertensives. Recently, NICE has changed
these guidelines and suggested that a 10% CVD risk rule
be implemented for the prescription of statins in the
under 75s.
Despite the increasing public awareness of the clinical
beneﬁts of statins within the UK, there have been rela-
tively few attempts to assess the level of initiation of
statin therapy for the primary prevention of CVD within
the UK population. Some studies have examined trends
in statin prescription within UK general practice,11–13
but these were performed using relatively small data sets
from the 1990s and early 2000s. Statin prescription
trends for the secondary prevention of CVD have also
been examined using small observational studies.14–16
Other studies17–19 have examined trends in the prescrip-
tion of statins within Europe, without a speciﬁc focus on
prescription practice within the UK. Recently, there have
been some small observational studies concerning statin
prescriptions within the UK,20 21 but a recent large-scale
analysis of the initiation rates of statin therapy within the
UK population has not been undertaken.
Electronic health records in UK primary care allow a
more thorough examination of statin use. We use such
data to perform an analysis of statin therapy initiation
rates for the primary prevention of CVD within the UK
population from 2004 to 2012. Our principal aim is to
examine whether there is any variation in the rate of ini-
tiation of statin therapy between the four UK countries
and the extent to which any differences observed can be
explained by demographic and/or socioeconomic
factors. Furthermore, within England, we examine the
extent to which statin therapy initiation rates vary
between different regions.
DATA AND METHODS
THIN database
We used data from The Health Improvement Network
(THIN) database (http://www.thin-uk.com), one of the
largest sources of UK primary care data. The database
contains anonymised patient records collected at over
500 UK general practices, including patient demograph-
ics, consultation information and patient therapy
records, linked over time. Over 98% of the UK popula-
tion are registered with a general practice22 and THIN is
regarded as broadly representative of the general UK
population.23 The database also includes information on
the Townsend score, a measure of social deprivation,
categorised into ﬁve quintiles from one (least deprived)
to ﬁve (most deprived).
Our study
We chose to examine statin initiation levels in individuals
with no history of CVD events during the period 2004–
2012. We chose to begin our analyses in 2004 because of
the introduction of the Quality and Outcomes
Framework (QOF) at that time. Patients who initiated
statins within 6 months of their date of registration at a
practice were excluded. This was done in an effort to
ensure that patients who moved practice and who had
previously initiated statin therapy would not be included.
The use of a 6-month ‘qualiﬁcation period’ appears rea-
sonable, since the vast majority of individuals receive
statins on monthly or at most three monthly prescrip-
tions and a 6-month ‘qualiﬁcation period’ has been
used in other studies that used THIN.24–26 The principal
outcome of interest is the number of statin therapy
initiations during the time period 2004–2012. Time is
accounted for explicitly by measuring the total patient
time ‘at risk’ (where ‘at risk’ implies ‘eligible for statin
therapy initiation’) during this period and the time until
ﬁrst statin prescription or end of follow-up at the patient
level. Important patient level and practice level variables
such as gender, age, Townsend score quintile, UK
country and strategic health authority (SHA; English
practices) were also recorded. We note that SHAs were
abolished in March 2013; however, we feel that SHAs
remain a useful variable for a comparison of English
regions.
Statistical analyses
The main outcome of interest is the statin therapy initi-
ation rate per 1000 person-years. For each individual, the
person-years of follow-up were calculated as running
from the latest of: 18th birthday, practice registration date
or 1 January 2004 to the earliest of: date of ﬁrst statin
prescription, date of death, date of ﬁrst CVD event, date
of transfer from practice or 31 December 2012. As such,
only those adult patients who had neither experienced a
CVD event nor had previously been prescribed statins
were included. The statin therapy initiation rate was esti-
mated both within each practice and using data from all
practices. Furthermore, statin therapy initiation rates
were estimated within each country of the UK and for
each strategic health authority within England.
We used Poisson regression models, with log (person-
years at risk) as an offset term, to estimate the rate of
statin therapy initiation with regard to gender, age group
and Townsend score quintile. To account for clustering
of individuals within practices, we included practice level
random effects. Age was classiﬁed into 12 groups accord-
ing to age in years (18–39, 40–49, 50–54, 55–59, 60–64,
65–69, 70–75, 75–80, 80–85, 85–90, 90–95 and 95+).
English practices contributed the majority of data and
so we felt that it was appropriate to examine possible dif-
ferences in statin therapy initiation rates between differ-
ent regions of England. Before 1 April 2013, primary
care within England was governed by 10 SHAs: London,
East Midlands, West Midlands, East of England, North
East England, North West England, South Central,
South East Coast, South West England and Yorkshire
and Humber. Although SHAs have since been replaced
by smaller clinical commissioning groups, the SHAs
existed while our data were collected and we feel that a
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comparison of rates between different SHAs could be
important in highlighting possible differences in statin
therapy initiation rates within England. Table 1 sum-
marises the number of practices within the different
SHAs in our data.
Data manipulation was carried out using STATA V.13
with other statistical analyses, including all modelling,
undertaken using the R statistical package (V.3.0.2).
RESULTS
We analysed data from 554 GP practices across the UK
(by country: England: 406, Northern Ireland: 23,
Scotland: 85, Wales: 40) using records from 4 820 885
individuals. Table 2 provides a summary of cohort demo-
graphics stratiﬁed by UK country. There were slightly
more females than males included in our analyses, pos-
sibly because, in general, females are more likely than
males to consult their GP regularly.27 Age at cohort
entry was broadly similar between countries. We see that,
across all countries, there were similar proportions of
patients in Townsend score quintiles 2–4 with slightly
larger and smaller proportions in quintiles 1 and 5,
respectively. This distribution of Townsend score quin-
tiles is seen within England but not for the other coun-
tries of the UK, with Northern Ireland, Scotland and
Wales tending to have higher proportions of patients in
more deprived Townsend score quintiles.
Figure 1 shows a plot of the estimated statin therapy ini-
tiation rate by practice, with a solid red line showing the
mean estimated statin therapy initiation rate using data
from all practices and the dashed red lines showing this
mean ±2SD(sample SD). Although many practices have
estimated initiation rates close to the overall mean rate of
14.91 per 1000 person-years, there exists substantial vari-
ation in rates between different practices, with estimated
initiation rates ranging from 0.83 to 38.26 initiations per
1000 patient-years. Seven practices have a rate lower than
two sample SDs below the estimated mean initiation rate
and 28 practices have a rate greater than two sample SDs
above the estimated mean initiation rate. Figure 2 shows
a similar plot, but with practices grouped according to
UK country. Practices within England and Scotland yield
very similar mean estimated initiation rates, whereas
those in Northern Ireland and Wales have a slightly
higher mean estimated initiation rate. In addition, vari-
ation in estimated rates appears slightly smaller within
Northern Ireland, although we note the smaller number
of Northern Irish practices.
Table 3 shows results from ﬁtted models. A compari-
son of the adjusted and unadjusted initiation rates shows
that even after accounting for patient demographics, ini-
tiation rates within Northern Ireland and Wales are
greater than that in England, whereas the rate in
Scotland is slightly lower than that in England.
Regions within England
Figure 3 shows a plot of the estimated statin therapy initi-
ation rate by practice within England, but with practices
grouped according to SHA. Solid red horizontal lines
denote the within SHA mean initiation rate and red
dashed lines denote a mean ±2SD(sample SD) for initi-
ation rate within each SHA. This plot shows that there is
considerable variation in initiation rates between practices
within each region. Table 4 provides a numerical compari-
son of estimated initiation rates, with a practice-speciﬁc
random effect to account for the clustering of patients
within practices. Prior to adjustment for the demographic
variables (columns 2 and 3), we see that observable differ-
ences in initiation rates exist between the different SHAs,
with the West Midlands, Yorkshire and Humber, North
West and North East SHAs showing slightly higher rates
than those seen in London and the South of England.
After accounting for demographic variables (column 4),
these differences are less marked, although the North
West region appears to have a signiﬁcantly higher initi-
ation rate when compared to London. Furthermore, the
East of England, South Central, South East Coast and
South West SHAs exhibit signiﬁcantly lower initiation rates
when compared to the London, East Midlands, West
Midlands, Yorkshire and Humber and North East SHAs,
even after accounting for demographic variables.
Gender, age group and Townsend score quintile
Finally, we examined the statin therapy initiation rates
controlling for gender, age group and the Townsend
score quintile, including a practice level random effect.
Table 5 provides a summary of these results. For age
group, we see that the initiation rate generally increases
with age, and this occurs until patients reach 75 years
whence rates begin to decrease. Males tend to have
higher estimated initiation rates than females. Initiation
rates for males appear to decrease slightly as the
Townsend score quintile increases (ie, as areas become
more socially deprived); however, once age distribution is
accounted for (5th main column of table 5), this trend is
no longer seen. Estimated unadjusted statin therapy initi-
ation rates are broadly similar for females across all
Townsend score quintiles. However, age-adjusted statin
Table 1 The number of practices within each strategic
health authority (SHA)
SHA
Number of practices
(percentage of English practices)
London 63 (15.51)
East Midlands 19 (4.68)
East of England 36 (8.87)
West Midlands 44 (10.84)
North East 15 (3.69)
North West 61 (15.02)
Yorkshire and
Humber
17 (4.19)
South Central 51 (12.56)
South East Coast 47 (11.58)
South West 53 (13.05)
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therapy initiation rates appear to increase in females as
the Townsend score quintile increases (ie, as areas
become more socially deprived).
DISCUSSION
Findings
We found considerable variation in statin therapy initi-
ation rates between different practices across the UK.
These rates were similar in England and Scotland but in
Wales and Northern Ireland were 18% (95% CI 5% to
32%) to 40% (95% CI 20% to 62%) higher, even after
accounting for the possible differences in patient demo-
graphics and the clustering of patients with practices,
between countries. Considerable variation in the initi-
ation rate was observed between different English regions
after accounting for differences in patient demographics.
The North West of England had a signiﬁcantly higher ini-
tiation rate when compared to London, Yorkshire and
Humber, North East England, East Midlands and West
Midlands SHAs. Furthermore, the East of England, South
Central, South East Coast and South West SHAs had sig-
niﬁcantly lower estimated initiation rates when compared
to this group of SHAs.
Summary statistics have indicated that regional differ-
ences in CVD morbidity exist within the UK.28 It is pos-
sible that some difference in statin therapy initiation rates
may be explained by the difference in underlying CVD
risk within the population served by the practices, such as
dietary habits, the levels of smoking and diabetes, low-
density lipoprotein (LDL) cholesterol level, hypertension
and body mass index (BMI) among others. Previous
research has shown that differences between practice pre-
scribing rates for statins were positively related to the rate
of coronary heart disease (CHD) hospital diagnoses and
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Figure 1 Plot showing the estimated statin therapy initiation rate
for each of the 554 general practitioner practices. The solid red
line indicates the sample mean statin therapy initiation rate. The
dashed red lines indicate this sample mean±2SD(sample SD).
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negatively associated with deprivation.13 29 30 Examining
data from 2010, Scotland has a higher rate of myocardial
infarction than England, and similarly the North East
and North West regions of England have higher rates of
myocardial infarction with the South East and East of
England reporting the lowest rates.28 Although our study
focused on statin prescription for primary prevention,
our ﬁndings concur with some of these observations.
Initiation rates were generally lower in females com-
pared to males and rates tended to increase with age for
both genders, until approximately 75 years, after which
rates generally declined. After accounting for age group,
initiation rates increased slightly as the Townsend score
quintile increased for both males and females. The risk
of CHD among middle-aged people is 2–5 times more
common in males than females, but for both genders
the risk of CHD increases with age and the risk of CHD
in older males and females is similar.31 Our ﬁndings
suggest that prescribing was lower in women than men
across all age groups with the exception of those over
75 years of age who were prescribed statins at the same
rate irrespective of their gender. The lower rates of pre-
scribing in the over 75s, despite their heightened risk of
CHD, might suggest that primary prevention of CVD in
the elderly could be improved. Nevertheless, our ﬁnd-
ings represent an improvement in practice. A previous
recent study suggested that patients over 75 years of
age were unlikely to be prescribed a statin for the
primary prevention of CVD irrespective of their
gender.13 It is likely that, with the absence of risk assess-
ment methods in older people, GP could beneﬁt from
clearer guidance on risk assessment for people above
the age of 75 years.
Our data clearly indicate that initiation of stain
therapy increased with deprivation (after accounting for
age). Once again, this suggests a change in GPs’
Figure 2 Plot showing the estimated statin therapy initiation rate for each of the 554 general practitioner practices, stratified by
UK country. The solid red line indicates the sample mean statin therapy initiation rate within a country. The dashed red lines
indicate this sample mean ±2SD(sample SD) within a country.
Table 3 Summary of country results
Country
Estimated statin initiation
rate (estimated 95% CI)
Unadjusted relative
statin initiation rates
Adjusted relative
statin initiation rates*
England 14.82 (14.37 to 15.28) 1 1
Northern Ireland 18.52 (16.23 to 21.15) 1.25 (1.09 to 1.43) 1.40 (1.20 to 1.62)
Scotland 14.63 (13.64 to 15.69) 0.99 (0.91 to 1.07) 0.92 (0.84 to 1.00)
Wales 17.06 (15.49 to 18.78) 1.15 (1.04 to 1.27) 1.18 (1.05 to 1.32)
The second column shows unadjusted estimated rates for each country, with the third column showing rates for Scotland, Northern Ireland
and Wales relative to a fixed rate of 1 unit per 1000 person-years for England. The fourth column shows these relative rates but where rates
are adjusted to account for gender, age group in years and Townsend score quintile.
*Rates adjusted for gender, age group and Townsend score quintile.
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prescribing behaviour. Previous data suggested that prac-
tices with higher deprivation indices prescribed fewer
statins to their patients than those in less deprived prac-
tices.32 However, our ﬁndings suggest that these inequal-
ities in prescribing based on deprivation have narrowed
since the study by Packham et al.
Strengths and limitations
A clear strength of this study is the large sample size
which reﬂects the general UK population and allows the
modelling of quantities of interest, controlled for a
range of factor variables, without the problem of small
group sizes in the model ﬁtting process. In addition,
since most GPs generate prescriptions electronically, the
nature of the THIN database allows us to accurately
monitor statin prescriptions in a detailed manner, by
patient, longitudinally. We feel that this has allowed us to
make informed and comprehensive assessment statin
therapy initiation rates for primary prevention of CVD,
within the UK population.
Figure 3 Plot showing the statin initiation rate for each practice, stratified by strategic health authority (indicated by an icon for
each practice). The solid red lines show the estimate of the statin initiation rate using data from within a strategic health authority.
The dashed red lines indicate sample mean ±2SD(sample SD) within a strategic health authority (EM, East Midlands; NE, North
East; NW, North West; SCen, South Central; SECoast, South East Coast; SW, South West; WM, West Midlands).
Table 4 Estimated statin therapy initiation rates for different strategic health authorities (SHA) within England
Strategic health authority
Statin initiation rate
(estimated 95% CI)
Unadjusted relative
statin initiation rate
Adjusted relative
statin initiation rate*
London 13.33 (12.31 to 14.43) 1 1
East Midlands 15.17 (13.30 to 17.30) 1.14 (0.98 to 1.33) 0.88 (0.73 to 1.05)
East of England 13.91 (12.58 to 15.37) 1.04 (0.92 to 1.19) 0.81 (0.71 to 0.94)
West Midlands 15.76 (14.44 to 17.21) 1.18 (1.05 to 1.33) 0.96 (0.84 to 1.09)
North East 16.47 (14.17 to 19.15) 1.24 (1.04 to 1.47) 0.96 (0.79 to 1.16)
North West 18.03 (16.72 to 19.44) 1.35 (1.21 to 1.51) 1.16 (1.02 to 1.31)
Yorkshire and Humber 17.37 (15.07 to 20.01) 1.30 (1.11 to 1.53) 0.97 (0.81 to 1.17)
South Central 12.75 (11.77 to 13.81) 0.96 (0.86 to 1.07) 0.73 (0.64 to 0.83)
South East Coast 13.78 (12.66 to 15.00) 1.03 (0.92 to 1.16) 0.83 (0.73 to 0.95)
South West 14.99 (13.83 to 16.25) 1.13 (1.00 to 1.26) 0.80 (0.71 to 0.91)
The first column shows overall rate estimates, the second column shows relative statin therapy initiation rates and the third column shows
statin therapy initiation rates adjusted for chosen factors. The second column shows unadjusted estimated rates for each SHA, with the third
column showing rates for non-London SHAs relative to a fixed rate of 1 unit per 1000 person-years for the London SHA. The fourth column
shows these relative rates but where rates are adjusted to account for gender, age group and Townsend score quintile.
*Rates adjusted for gender, age group and Townsend score quintile.
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Table 5 Estimated statin therapy initiation rates for age groups and Townsend score quintiles, stratified according to gender
Age group
(years)
Statin initiation rate per
1000 person-years (estimated 95% CI)
Unadjusted relative statin
initiation rate Adjusted relative statin initiation rate*
Males Females Males Females Males Females
18–39 1.63 (1.56 to 1.70) 0.93 (0.89 to 0.98) 1 0.57 (0.55 to 0.60) 1 0.57 (0.55 to 0.60)
40–49 10.79 (10.42 to 11.17) 6.41 (6.18 to 6.65) 6.63 (6.43 to 6.83) 3.94 (3.81 to 4.07) 6.69 (6.49 to 6.89) 3.98 (3.85 to 4.11)
50–54 23.03 (22.23 to 23.86) 15.87 (15.29 to 16.46) 14.15 (13.71 to 14.60) 9.75 (9.43 to 10.08) 14.31 (13.88 to 14.77) 9.88 (9.56 to 10.21)
55–59 34.69 (33.51 to 35.91) 25.36 (24.47 to 26.27) 21.32 (20.68 to 21.98) 15.58 (15.10 to 16.08) 21.60 (20.95 to 22.26) 15.82 (15.33 to 16.32)
60–64 51.63 (49.89 to 53.42) 36.33 (35.08 to 37.61) 31.72 (30.78 to 32.69) 22.32 (21.64 to 23.02) 32.17 (31.23 to 33.14) 22.68 (22.00 to 23.38)
65–69 67.11 (64.82 to 69.47) 48.26 (46.60 to 49.98) 41.24 (39.99 to 42.52) 29.65 (28.75 to 30.59) 41.80 (40.55 to 43.08) 30.10 (29.19 to 31.03)
70–74 70.77 (68.28 to 73.35) 57.43 (55.44 to 59.50) 43.48 (42.12 to 44.89) 35.29 (34.20 to 36.42) 44.04 (42.68 to 45.46) 35.70 (34.61 to 36.83)
75–79 43.64 (41.91 to 45.44) 47.69 (45.95 to 49.51) 26.81 (25.84 to 27.83) 29.31 (28.34 to 30.31) 27.10 (26.12 to 28.11) 29.52 (28.56 to 30.52)
80–84 32.39 (30.89 to 33.97) 34.83 (33.43 to 36.28) 19.90 (19.04 to 20.81) 21.40 (20.61 to 22.22) 20.06 (19.20 to 20.96) 21.45 (20.67 to 22.26)
85–89 22.10 (20.65 to 23.65) 23.54 (22.39 to 24.75) 13.58 (12.71 to 14.50) 14.47 (13.80 to 15.17) 13.66 (12.80 to 14.57) 14.46 (13.80 to 15.16)
90–94 12.47 (10.85 to 14.32) 11.20 (10.26 to 12.24) 7.66 (6.67 to 8.79) 6.88 (6.31 to 7.51) 7.69 (6.71 to 8.81) 6.88 (6.31 to 7.49)
95+ 4.51 (2.89 to 7.04) 5.03 (4.08 to 6.21) 2.77 (1.78 to 4.32) 3.09 (2.51 to 3.82) 2.77 (1.79 to 4.30) 3.09 (2.51 to 3.81)
Townsend
score
quintile
Statin initiation rate per
1000 person-years (estimated 95% CI)
Unadjusted relative statin
initiation rate Adjusted relative statin initiation rate†
Males Females Males Females Males Females
1 18.15 (17.45 to 18.87) 13.26 (12.72 to 13.82) 1 0.73 (0.70 to 0.76) 1 0.66 (0.65 to 0.67)
2 17.52 (16.82 to 18.24) 13.76 (13.19 to 14.36) 0.97 (0.92 to 1.01) 0.76 (0.72 to 0.79) 1.01 (0.99 to 1.02) 0.70 (0.69 to 0.72)
3 16.01 (15.35 to 16.70) 13.69 (13.11 to 14.29) 0.88 (0.84 to 0.92) 0.75 (0.72 to 0.79) 1.02 (1.01 to 1.04) 0.78 (0.76 to 0.79)
4 15.19 (14.52 to 15.88) 14.03 (13.41 to 14.68) 0.84 (0.80 to 0.88) 0.77 (0.74 to 0.81) 1.05 (1.03 to 1.07) 0.86 (0.85 to 0.88)
5 14.68 (13.93 to 15.46) 14.40 (13.66 to 15.18) 0.81 (0.76 to 0.86) 0.79 (0.75 to 0.84) 1.07 (1.05 to 1.09) 0.94 (0.92 to 0.96)
The first column shows overall rate estimates, the second column shows relative statin therapy initiation rates and the third column shows statin therapy initiation rates adjusted for chosen
factors.
*Rates adjusted for Townsend score quintile.
†Rates adjusted for age group.
O
’Keeffe
AG,etal.BM
J
Open
2015;5:e007207.doi:10.1136/bm
jopen-2014-007207
7
O
p
e
n
A
c
c
e
s
s
group.bmj.com
 o
n
 O
ctober 26, 2015 - Published by 
http://bmjopen.bmj.com/
D
ow
nloaded from
 
There are limitations to our methods and sample. We
are only using data from those who are registered with a
GP. However, in the UK, the vast majority of the popula-
tion is registered with a GP. We have accounted for socio-
demographic variables such as age, sex and social
deprivation. While these may be strongly correlated to
other factors that may determine initiation of statin pre-
scriptions, it is possible that primary initiation of statins
may be governed by factors that we have not captured by
the sociodemographic variables.
It is possible that the rate of statin therapy initiation is
related to measures such as smoking status, BMI, blood
pressure and LDL cholesterol level among others. While
it may have been desirable, at ﬁrst sight, to include such
variables in our analyses, we bear in mind the limitations
of primary care records. In particular, measures such as
BMI, blood pressure and LDL cholesterol level are not
recorded for all individuals and may be more likely to
exist for those patients who visit their GP more regularly
than others, or perhaps those who suffer from chronic or
recurrent health conditions.33 34 Naturally, such patients
would not be representative of the general UK popula-
tion and, as such, the inclusion of variables such as these
in our analyses might lead to substantial biases.
Conversely, basic demographic variables, such as age
group, gender and social deprivation status (taken from a
patient’s postcode), are available for the vast majority of
individuals who are registered with a GP, irrespective of
any health conditions exhibited by a patient, thereby jus-
tifying the use of such variables in our analyses.
Final conclusions
There is a considerable variation in the rate of initiation of
statins for primary prevention of CVD in 4 UK countries
and the 10 English regions. However, at the individual level,
there is insufﬁcient evidence to suggest that inequalities in
prescribing exist between the sexes and across various levels
of deprivation. GP may beneﬁt from guidance on statin pre-
scribing in people above the age of 75 years.
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